We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Fed. Circ. Asks Whether Endo's Opioid Patent Was Obvious

Law360 (December 6, 2018, 3:00 PM EST) -- Actavis LLC and Endo Pharmaceuticals Inc. faced questions from a Federal Circuit panel on Thursday regarding whether someone of ordinary skill could successfully develop Endo’s opioid painkiller Opana ER, amid Actavis’...
To view the full article, register now.

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

October 16, 2017

Law Firms

Companies

Government Agencies

Patents

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.